Pacira BioSciences, Inc. (PCRX)
Automate Your Wheel Strategy on PCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including PCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCRX
- Rev/Share 15.1869
- Book/Share 17.2564
- PB 1.4963
- Debt/Equity 0.797
- CurrentRatio 2.4146
- ROIC -0.0841
- MktCap 1195587354.0
- FreeCF/Share 3.4446
- PFCF 7.5006
- PE -11.5189
- Debt/Assets 0.4011
- DivYield 0
- ROE -0.1294
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PCRX | Truist | Sell | Hold | $8 | $25 | Jan. 30, 2025 |
News
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers.
Read More
Lost Money on Pacira BioSciences, Inc. (PCRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132147&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132114&wire=1 or contact Joseph E. Levi, Esq.
Read More
A Securities Fraud Lawsuit Has Been Filed Against Pacira BioSciences, Inc. And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=132011&wire=1 or contact Joseph E. Levi, Esq.
Read More
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024.
Read More
Shareholders that Lost Money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131969&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact Levi & Korsinsky
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131916&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 – PCRX
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131860&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
Published: February 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131633&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A LEADING NATIONAL FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX
Published: February 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131396&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / WHY: New York, N.Y., February 21, 2025.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit – PCRX
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131325&wire=1 or contact Joseph E. Levi, Esq.
Read More
A Lawsuit Has Been Filed Against Pacira BioSciences, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Read More
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131264&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131172&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131131&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW ORLEANS, LA / ACCESS Newswire / February 20, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS:PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the "Class Period").
Read More
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131124&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131101&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Pacira BioSciences, Inc. (PCRX)
- IPO Date 2011-02-03
- Website https://www.pacira.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Frank D. Lee
- Employees 788